Select data courtesy of the U.S. National Library of Medicine.

© 2026 DeepDyve, Inc. All rights reserved.

This site is protected by VikingCloud's Trusted Commerce program

    PWE-176 Prevalence, Management, And Healthcare Burden Of Irritable Bowel Syndrome (ibs) In Scotland

    McTaggart, S; Wyper, G; Harkins, L; Bishop, I; Bennie, M; Rance, M
    Gut·Jun 9, 2014

    PWE-176 Prevalence, Management, And Healthcare Burden Of Irritable Bowel Syndrome (ibs) In Scotland

    Abstract

    Introduction Using real-world healthcare, routinely collected information we investigated the prevalence of irritable bowel syndrome (IBS) and associated consumption of healthcare resources in the Scottish National Health Service. Methods A consultation records database covering 56 general practitioner (GP) practices in Scotland (approximately 255,000 people; 5.8% of the population) was used to identify consultations primarily due to IBS with GP or practice nurses between April 2009 and March 2011 (Read codes: IBS, constipation, diarrhoea). Read codes suggesting other causes of diarrhoea or constipation and patients with inflammatory bowel disease, diverticular disease, coeliac disease or bowel cancer were excluded. A national primary care prescription database was used to identify use of antispasmodics, laxatives or antidiarrhoeals. Referrals to outpatient clinics and acute hospital admissions between January and December 2011 in antispasmodic-treated patients were also analysed using national datasets. Results Based on consultation records, an estimated 341,180 adults (≥18 years) in Scotland suffer from IBS, representing an estimated prevalence of 7.7% (females: 9.8%; males: 5.5%). Patients consulted 1.05 times during 2010/11 for IBS symptoms and consulted more frequently overall than the general population (9.3 vs. 4.7 times per annum). During 2011, 142,738 adults received ≥1 prescription for antispasmodics, most commonly mebeverine (40.1%), hysocine butylbromide (35.7%) or peppermint (18.0%), giving an estimated prevalence of antispasmodic-treated IBS of 3.4% (females: 4.7%; males: 2.0%). One-third of these patients were also prescribed laxatives (24.5%), the antidiarrhoeal loperamide (6.7%) or both (2.5%). Of the antispasmodic-treated patients, 11,645 (9.0%) visited a gastroenterology outpatient clinic in 2011 (11.7% of all gastroenterology clinic attendances) and 1,869 (1.3%) were acutely admitted to hospital due to IBS or symptoms likely to be associated with IBS, most frequently constipation (80.3%). The average length of hospital stay was 2.1 days (2.4 days for admissions due to constipation). A further 1,141 people with no record of antispasmodic prescriptions were admitted with a primary diagnosis of IBS. Conclusion Based on consultation records, the estimated prevalence of IBS in Scotland is 7.7%, and 3.4% based on prescription records; these estimates exclude patients who do not consult a GP or who use laxatives alone or over-the-counter medicines. The prevalence estimates and levels of treatment in this study were consistent with other published information, and show that patients with IBS consume significant healthcare resources. Study commissioned by Almirall UK. Disclosure of Interest S. McTaggart Grant/research support from: This study was undertaken as a commercially contracted piece of work for Almirall UK, G. Wyper Grant/research support from: This study was undertaken as a commercially contracted piece of work for Almirall UK, L. Harkins Grant/research support from: This study was undertaken as a commercially contracted piece of work for Almirall UK, I. Bishop Grant/research support from: This study was undertaken as a commercially contracted piece of work for Almirall UK, M. Bennie Grant/research support from: This study was undertaken as a commercially contracted piece of work for Almirall UK, M. Rance Employee of: Almirall.

    Meet DeepDyve

    Get unlimited, instant access to over 150 million full-text scientific articles for less than the price of buying a single PDF.

    150M+Research Papers
    35M+Full-Text Streaming Papers
    25M+Open Access Papers
    $2/dayStarting Price
    DeepDyve Collection

    DeepDyve Collection

    Access top-tier journals without the top-tier price. We partner directly with the world’s leading academic publishers to bring you legally compliant, instant access. Read the latest findings from Springer, Wiley, Oxford University Press, and more—all in one subscription.

    Browse our collection of titles from leading publishers

    arXiv
    ChemRxiv
    Hindawi
    JAMA
    MDPI
    medRxiv
    NEJM
    Oxford University Press
    PLOS
    PubMed
    Sage
    Springer Nature
    Wiley
    Wolters Kluwer
    AI Research Assistant

    AI Research Assistant

    Accelerate your research with our advanced AI tools. Chat directly with your uploaded papers, and DeepDyve’s 50M+ LitStream and OA collections of full-text papers. AI responses come directly from the literature, footnoted and sourced, to provide the most authoritative and verifiable responses. AI outputs powered by OpenAI and Anthropic Claude. AI Smart Folders (coming soon)

    Stop wasting time on paywalls, pirated sites and scattered journal portals

    Streamline your research workflow with DeepDyve's comprehensive literature management solution for less than the price of buying a single PDF.

    Try 1 month for $0